Cenicriviroc

Phase 2Small molecule

TTobira Therapeutics, Inc.

Cenicriviroc is one of 13 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Terminated

COVID-19Phase 2

Terminated

Competition

Competitive Landscape

311 competitors in COVID-19

#DrugCompanyPhaseTrials

Cenicriviroc

TTobira Therapeutics, Inc.

Phase 2

3 2

Other Tkis

Bayer

Preclinical

1 3

Serology

UUniversity Hospital Center of Martinique

Preclinical

3 4

Pfizer-Biontech COVID-19 MRNA Vaccine

Pfizer

Preclinical

1 5

Administration of Almitrine

CCentre Hospitalier Universitaire de Nice

Preclinical

1 6

Tpa

UUniversity of Florida

Preclinical

1 7

Thrombolytic

FFaculty Hospital Kralovske Vinohrady

Preclinical

1 8

SARS-Cov-2 Bivalent MRNA Vaccine

AAIM Vaccine Co., Ltd.

Preclinical

2 9

Serological Test

CCentre Hospitalier de Cornouaille

Preclinical

2 10

Exebacase

CContraFect

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Active, not recruiting

COVID-19

NCT04488081

Clinical

Trials by Indication[1]

COVID-193 trials

Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

Terminated·—·Phase 2·NCT04500418·45 enrolled

Immune Modulators for Treating COVID-19

Completed·DDaniel Benjamin·Phase 3·NCT04593940·1,971 enrolled

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT04488081·1,500 enrolled

Hepatitis3 trials

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT02217475·289 enrolled

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

Terminated·TTobira Therapeutics, Inc.·Phase 3·NCT03028740·1,778 enrolled

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Terminated·TTobira Therapeutics, Inc.·Phase 2·NCT03059446·167 enrolled

Antiretroviral Treatment1 trial

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT01338883·143 enrolled

Type 2 Diabetes Mellitus1 trial

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT02330549·45 enrolled

Fibrosis1 trial

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Completed· Novartis logo

Novartis·Phase 2·NCT03517540·193 enrolled

7 more indications

Sclerosing Cholangitis1 trial

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Completed·TTobira Therapeutics, Inc.·Phase 2·NCT02653625·24 enrolled

Single Dose1 trial

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT01827540·20 enrolled

Hepatic Impairment1 trial

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Completed· AbbVie logo

AbbVie·Phase 1·NCT03376841·16 enrolled

Age1 trial

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT02684799·48 enrolled

Cognitive impairment1 trial

Effect of Cenicriviroc on HIV Neurocognitive Impairment

Completed·UUniversity of Hawaii·Phase 2·NCT02128828·20 enrolled

Moderate Hepatic Impairment1 trial

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT02120547·31 enrolled

Unspecified1 trial

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

Completed·TTobira Therapeutics, Inc.·Phase 1·NCT02342067·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Cenicriviroc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenicriviroc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenicriviroc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tobira Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTobira Therapeutics, Inc.

Cenicriviroc

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

COVID-193 trials

Hepatitis3 trials

Antiretroviral Treatment1 trial

Type 2 Diabetes Mellitus1 trial

Fibrosis1 trial

Sclerosing Cholangitis1 trial

Single Dose1 trial

Hepatic Impairment1 trial

Age1 trial

Cognitive impairment1 trial

Moderate Hepatic Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News